I disagree with jonesingPan on the interests of big pharma. The more PAB moves ahead under its' own funds the closer it gets to a marketable product . Should PAB progress satisfactorily to and through stage 1 trials it's all over for big pharma to buy at less than many billions. I've been with PAB virtually since its' listing and have a friend or 2 in this biomed science who speak highly of the successes of PAB and who express confidence in their product. To those who continually naysay why not just leave, hopefully at a very low sp.
Ann: Change of Director's Interest Notice, page-4
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
-0.001(14.3%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.6¢ | $5.77K | 961.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 2737126 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 2551812 | 3 |
View Market Depth
| Last trade - 10.20am 06/08/2024 (20 minute delay) ? |
| PAB (ASX) Chart |